Inogen
Inogen's revenue rose 3.9% to $349 million in fiscal 2025. Its operating margin was −8.7%, up from −12.7% a year earlier. Free cash flow was −$14 million, against $3 million a year earlier. The diluted share count rose 12.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Inogen does
Inogen is a medical technology company focused on breathing health. Its main products are portable oxygen concentrators, small battery-powered machines that take in the air around a patient and supply extra oxygen, marketed as Inogen One and Inogen Rove. They are used for long-term oxygen therapy by people with chronic lung conditions. It also sells Simeox, a device that helps clear mucus from airways, and has started distributing a stationary oxygen concentrator and CPAP masks for sleep apnea in the United States.
It earns money in three main ways: selling to home medical equipment providers, distributors and resellers; selling directly to consumers; and renting devices directly to consumers. Much of its rental revenue comes from Medicare, private insurers and Medicaid paying for patients.
It entered a collaboration in January 2025 with the Chinese company Jiangsu Yuyue Medical Equipment & Supply, known as Yuwell, to distribute certain respiratory products in the United States. It competes with other makers and distributors of portable oxygen concentrators.
Its biggest risks, as it describes them
- It faces strong competition from other makers of portable oxygen concentrators and respiratory products.
- A limited number of customers account for a large part of its sales.
- Interruptions in the supply of components and products could hurt its manufacturing and sales.
- Tariffs and trade restrictions could raise its costs and disrupt its supply chain.
- Much of its revenue depends on reimbursement from Medicare, private payors and Medicaid, and rates or policies could change.
Income statement
From fiscal 2016 to 2019, earnings per share fell 1.0% a year and net income grew 0.6% a year, as new shares raised the share count by 5% and diluted each share's earnings. Inogen then lost money in fiscal 2020, 2021, 2022, 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 246 | — | 128 | 114 | 120 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 5.3x | 4.7x | 2.9x | 2.4x | 3.1x |
| Quick ratio | 4.8x | 4.1x | 2.5x | 2.1x | 2.7x |
Cash flow
Projections
Project Inogen's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Inogen shares on the open market, and 1 insider sold $142,519, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | Boyer Jennifer M YiEVP Entrprs Enblmnt, Ch HR Off | Sold plan | 10,938 | $6.60 | $72,191 | Form 4 |
| May 29, 2026 | Boyer Jennifer M YiEVP Entrprs Enblmnt, Ch HR Off | Sold plan | 10,770 | $6.53 | $70,328 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −19.0% | 7.1% | −0.1% |
| Altman Z'' | 1.06 | 1.25 | 2.26 |
| Accruals ratio | −27.1% | −13.4% | −3.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Inogen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Inogen | FY25 | 3.9% | −8.7% | −3.9% | — | — | — | |
| Tactile Systems Technology | FY25 | 12.5% | 8.9% | 12.3% | 12.6% | −2.3x | 8 | Compare |
| InMode | FY25 | −6.2% | 23.1% | 22.8% | — | — | — | Compare |
| Angiodynamics | FY26 | 9.5% | −12.5% | 0.2% | −24.6% | — | 4 | Compare |
| PROCEPT BioRobotics | FY25 | 37.2% | −33.7% | −18.9% | −65.4% | — | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 203 | 249 | 358 | 362 | 308 | 358 | 377 | 316 | 336 | 349 |
| Revenue growth | 27.6% | 23.0% | 43.6% | 1.1% | −14.8% | 16.1% | 5.4% | −16.3% | 6.3% | 3.9% |
| Gross profit | 97 | 121 | 179 | 172 | 138 | 176 | 154 | 127 | 155 | 154 |
| Research and development | 5 | 5 | 7 | 9 | 14 | 17 | 22 | 21 | 22 | 19 |
| Operating income | 23 | 28 | 38 | 20 | −12 | 9 | −85 | −109 | −42 | −30 |
| Net income | 20 | 21 | 52 | 21 | −6 | −6 | −84 | −102 | −36 | −23 |
| Diluted EPS (US$) | 0.97 | 0.96 | 2.30 | 0.94 | −0.27 | −0.28 | −3.67 | −4.42 | −1.52 | −0.86 |
| Diluted shares (millions) | 21 | 22 | 22 | 22 | 22 | 22 | 23 | 23 | 24 | 27 |
| Cash flow | ||||||||||
| Cash from operations | 31 | 60 | 60 | 41 | 37 | 24 | −38 | −3 | 6 | −11 |
| Capital expenditure | 2 | 3 | 8 | 3 | 4 | 6 | 3 | 5 | 3 | 2 |
| Free cash flow | 29 | 58 | 52 | 37 | 33 | 18 | −41 | −8 | 3 | −14 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 4 | 0 | 70 | 0 | 0 | 0 | 30 | 0 | 0 |
| Stock-based compensation | 7 | 10 | 13 | 9 | 8 | 11 | 12 | 7 | 7 | 8 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 114 | 174 | 240 | 209 | 231 | 246 | — | 128 | 114 | 120 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 214 | 275 | 376 | 447 | 462 | 490 | 405 | 326 | 296 | 299 |
| Total liabilities | 32 | 48 | 66 | 103 | 112 | 119 | 108 | 121 | 122 | 106 |
| Shareholders' equity | 182 | 227 | 310 | 345 | 350 | 370 | 297 | 205 | 174 | 192 |
| Margins and ratios | ||||||||||
| Gross margin | 48.0% | 48.6% | 49.9% | 47.5% | 44.8% | 49.3% | 40.7% | 40.1% | 46.1% | 44.2% |
| Operating margin | 11.3% | 11.1% | 10.6% | 5.5% | −3.9% | 2.6% | −22.6% | −34.6% | −12.7% | −8.7% |
| Net margin | 10.1% | 8.4% | 14.5% | 5.8% | −1.9% | −1.8% | −22.2% | −32.5% | −10.7% | −6.5% |
| Free cash flow margin | 14.4% | 23.1% | 14.5% | 10.3% | 10.6% | 5.1% | −10.8% | −2.7% | 0.8% | −3.9% |
| Rule of 40 (growth + FCF margin) | 42.0% | 46.1% | 58.1% | 11.4% | −4.2% | 21.1% | −5.5% | −19.0% | 7.1% | −0.1% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | 13.0% | 10.3% | 19.3% | 6.4% | −1.7% | −1.8% | −25.1% | −40.8% | −18.9% | −12.4% |
| Return on assets | 10.9% | 8.6% | 15.9% | 5.1% | −1.3% | −1.3% | −18.7% | −28.0% | −11.5% | −7.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |